DNMT1

DNA (cytosine-5)-methyltransferase 1 · P26358 · DNMT1 on Sugi Atlas →

64,059 patent compounds predicted against DNMT1, 45,789 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL231959	0.64	8/20
SCHEMBL231960	0.64	8/20
S-Adenosylhomocysteine (SCHEMBL8836)	1.00	7/20
SCHEMBL133528	0.49	7/20
SCHEMBL8345	0.63	6/20
SCHEMBL20268	0.63	6/20
SCHEMBL197813	0.63	6/20
SCHEMBL198512	0.63	6/20
SCHEMBL207023	0.63	6/20
Ibacitabine (SCHEMBL225402)	0.63	6/20
Ibacitabine (SCHEMBL225403)	0.63	6/20
Ibacitabine (SCHEMBL244921)	0.63	6/20
SCHEMBL149389	0.57	6/20
Decitabine (SCHEMBL4006)	1.00	5/20
Decitabine (SCHEMBL117721)	1.00	5/20
Decitabine (SCHEMBL172264)	1.00	5/20
Decitabine (SCHEMBL120951)	0.97	5/20
Decitabine (SCHEMBL168918)	0.67	5/20
Cladribine (SCHEMBL58609)	0.62	5/20
Adenosine (SCHEMBL192733)	0.61	5/20

Clinical trials — most relevant to DNMT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation	PHASE4	COMPLETED
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC	PHASE3	UNKNOWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	PHASE1/PHASE2	COMPLETED
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	RECRUITING
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	PHASE2	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	PHASE1	COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer	PHASE1	SUSPENDED
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)	PHASE1	RECRUITING
FdCyd and THU for Advanced Solid Tumors	PHASE1	COMPLETED
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors	PHASE1	COMPLETED
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma	PHASE1	COMPLETED
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer	EARLY_PHASE1	COMPLETED
DNA Methylation and Perioperative Pain Treatment	nan	COMPLETED
Effect of DNMT SNPs on DNA Methylation in Primary ITP	nan	UNKNOWN
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL	nan	RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD	nan	NOT_YET_RECRUITING
Analysis of DNA Methylation in Spondyloarthritis	nan	COMPLETED
Exploratory Study of Rectal Mucus for Diagnosing Disease	nan	COMPLETED
Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a DNMT1 binder may also engage these)

Protein	Name	Similarity
P13864	—	1.000	P13864 →
Q24K09	—	1.000	Q24K09 →
Q92072	—	1.000	Q92072 →
BPTF	Nucleosome-remodeling factor subunit BPTF	1.000	landscape →
P79922	—	0.999	P79922 →
O23273	—	0.998	O23273 →
Q9Z330	—	0.998	Q9Z330 →
Q27746	—	0.998	Q27746 →
Q8WML3	—	0.998	Q8WML3 →
G5EC37	—	0.997	G5EC37 →
B1WBA5	—	0.996	B1WBA5 →
Q09354	—	0.996	Q09354 →
Q99PI5	—	0.996	Q99PI5 →
Q8IRH5	—	0.995	Q8IRH5 →
Q28Z18	—	0.995	Q28Z18 →
G5EGA3	—	0.995	G5EGA3 →
Q5SVQ0	—	0.995	Q5SVQ0 →
P41511	—	0.995	P41511 →
Q9M0S8	—	0.995	Q9M0S8 →
Q8BZ21	—	0.995	Q8BZ21 →
P06701	—	0.995	P06701 →
Q5HZJ0	—	0.995	Q5HZJ0 →
Q60DW3	—	0.995	Q60DW3 →
A2Y4R8	—	0.995	A2Y4R8 →
A0A0R4IBK5	—	0.994	A0A0R4IBK5 →
Q80WL2	—	0.994	Q80WL2 →
A5DQ88	—	0.994	A5DQ88 →
Q9BWT1	—	0.994	Q9BWT1 →
P36795	—	0.994	P36795 →
Q08876	—	0.994	Q08876 →